Edwyn
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $931 | $1,106 | $1,137 | $1,159 | $1,220 |
| Gross Profit | $633 | $756 | $770 | $770 | $790 |
| Operating Income | $237 | $297 | $299 | $207 | $102 |
| Net Income | $140 | $272 | $285 | $168 | $73 |
Over the five-year period, BIO-TECHNE Corp’s revenue has shown a generally upward trend, growing from USD 931 million in 2021 to USD 1,220 million in 2025. The steepest increase occurred in 2022, when revenue jumped approximately 19% compared to 2021, accompanied by similar gains in gross profit (rising to around USD 756 million) and operating income (reaching nearly USD 297 million). Net income in 2022 exhibited a notable spike, almost doubling from USD 140 million in 2021 to USD 272 million, suggesting potential operational improvements or favorable market conditions that year. From 2022 to 2023, however, growth moderated across the board, with revenue and operating metrics increasing by only a few percentage points. Beginning in 2024, the company experienced significant pressure on profitability. Although revenue and gross profit continued to increment modestly, operating income dropped sharply by about 30% in 2024 and continued to decline by nearly 50% in 2025. Net income similarly fell by over 40% in 2024 and by more than 55% in 2025. These substantial declines in operating and net margins indicate a period of margin compression, potentially driven by rising costs, pricing pressures, or changes in operational efficiency. Overall, while BIO-TECHNE Corp has demonstrated robust top-line growth, the recent downward swing in profitability metrics raises concerns regarding the sustainability of its operational performance and suggests a need to address underlying cost or efficiency challenges to maintain long-term financial health.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.